Insulin Analogues and Cancer Risk
A series of research articles about the insulin analogue Lantus have been published recently by the European Association for the Study of Diabetes.
One of these studies in particular raised questions that the use of Lantus may be associated with an increase in cancer risk, particularly in people using Lantus as their sole source of insulin treatment.
It is important to note that all of these studies were observational in nature and involved primarily people with insulin-dependant type 2 diabetes. This means the researchers could only draw conclusions from general statistical trends and couldn’t exclude the possibility that their study results may be influenced by other factors including environment or lifestyle.
0 Comments 




